레고켐바이오
History
  • 2014 ~

    2017
    01.LCB enters into research licensing agreement with Takeda to develop next-generation ADC Candidates.
    01.LCB obtains patent for Protein-active agent conjugates and method for preparing the same.
    2016
    12.LCB enters licensing agreement with RMX Biopharma for LCB01-0371 (gram-positive antibiotic) regarding China market.
    08.LCB extends designation as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy
    08.LCB Initiates clinical trial phase I of oxazolidinone antibiotic LCB01-0371 (IV)
    07.LCB sets up a Joint Venture for the global development of Cephalosporin antibiotic LCB10-0200
    06.LCB obtains patent for its novel linker chemistry (Compounds Comprising Self-immolative group)
    05.LCB initiates clinical trial phase II of oxazolidinone antibiotic LCB01-0371 (PO)
    05.Mechanical completion of API Plant I (LegoChem Pharma)
    2015
    12.Acquisition of Khanmed & Hanbul Pharma
    11.LCB enters into a Joint Research agreement with Theranyx
    08.LCB licenses out anti-Her2 ADC to Fosun Pharma for the Greater Chinese market
    2014
    10.LCB01-0371 (oxazolidinone antibiotic) is selected as a “PHARM NAVI” project by the MFDS
    (Ministry of Food and Drug Safety)
    09.Completion of clinical trial phase 1 for LCB02-0133 (FXa, Anti-Coagulant Candidate)
    08.LCB is designated as “K-Brain Power” Company by the Ministry of Trade, Industry and Energy.
  • 2010 ~ 2013

    2013
    08.LCB Initiates pre-clinical trial of cephalosporin antibiotic LCB10-0200
    07.LCB’s ADC (Antibody Drug Conjugate) is selected as an investment related project
    by the Small and Medium Business Administration (SMBA).
    05.LCB (141080) is listed on KOSDAQ through Initial Public Offering
    2012
    12.LCB enters into a collaboration agreement with AstraZeneca and license out
    its cephalosporion antibiotic candidate LCB10-0200
    12.LCB enters into a collaboration agreement with Green Cross to develop
    Next-generation Antibody-Drug Conjugates
    07.LCB enters into a collaboration agreement with Sanofi to develop novel oncologics
    06.LCB designated as an INNO-BIZ company
    03.CB named as “Emerging Company of the Year 2012” (BioSpectrum Aisa, Singapore)
    02.LCB initiates clinical trial phase I of FXa inhibitor anti-coagulant candidate LCB02-0133
    2011
    11.US FDA IND approval for anti-coagulant candidate LCB02-0133
    07.LCB02-0133(Anit-coagulant, FXa inhibitor) selected as Global New Drug Discovery Project
    by Korean Ministry of Education, Science, and Technology
  • 2006 ~ 2009

    2009
    12.LCB presents antibiotic study result at the 2009 “ICAAC” San Francisco
    06.LCB successfully license-out its preclinical stage Anti-coagulant candidate
    LCB02-0133 (FXa inhibitor)
    01.Joint research contract with The Catholic Univ. School of Medicine
    (ophthalmic medicine: Wondonin) is executed
    2008
    05.LCB receives Korean MOHW (Ministry of Health and Welfare) researching funding for
    oxazolidinone antibiotic candidate.
    2007
    09.LCB presents oxazolidinone antibiotic study result at the Chicago “ICAAC” Conference 2007
    2006
    05.LCB is founded